irinotecan liposomal (Rx)

Brand and Other Names:Onivyde
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

liposomal dispersion for injection

  • 43mg/10mL single-dose vial

Pancreatic Cancer

Indicated, in combination with fluorouracil and leucovorin, for metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy

Administer irinotecan liposomal prior to leucovorin and fluorouracil

70 mg/m² IV infused over 90 min q2wk

Premedicate with a corticosteroid and an antiemetic agent 30 min before irinotecan liposomal infusion (see Administration)

Dosage Modifications

Patients known to be homozygous for the UGT1A1*28 allele: 50 mg/m² IV infused over 90 min q2wk; increase dose to 70 mg/m² as tolerated in subsequent cycles

Serum bilirubin >ULN: No recommended dose

Interstitial lung disease: Discontinue drug

Anaphylactic reaction: Discontinue drug

Grade 3 or 4 adverse reactions

  • Withhold dose
  • Upon recovery to ≤grade 1, resume dose at:
    • First occurrence: Resume dose at 50 mg/m² or 43 mg/m² (patients homozygous for UGT1A1*28 without previous increase to 70 mg/m²)
    • Second occurrence: Resume dose at 43 mg/m² or 35 mg/m² (patients homozygous for UGT1A1*28 without previous increase to 70 mg/m²)
    • Third occurrence: Discontinue drug
  • Diarrhea
    • Withhold dose
    • Initiate loperamide for late-onset diarrhea of any severity
    • Administer IV or SC atropine 0.25-1 mg (unless clinically contraindicated) for early-onset diarrhea of any severity
    • Upon recovery to ≤grade 1, resume dose as described above

Dosing Considerations

Limitations of use: Not indicated as a single agent

Do not substitute irinotecan liposomal for other drugs containing irinotecan

Small Cell Lung Cancer (Orphan)

Orphan designation for treatment of small cell lung cancer

Sponsor

  • Ipsen Bioscience, Inc; 650 East Kendall Street; Cambridge, Massachusetts 02142

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and irinotecan liposomal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Diarrhea, grades 1-4 (59%)

            Fatigue/asthenia, grades 1-4 (56%)

            Vomiting, grades 1-4 (52%)

            Nausea, grades 1-4 (51%)

            Decreased appetite, grades 1-4 (44%)

            Late diarrhea, grades 1-4 (43%)

            Stomatitis, grades 1-4 (32%)

            Early diarrhea, grades 1-4 (30%)

            Lymphopenia, grades 3-4 (27%)

            Pyrexia, grades 1-4 (23%)

            Fatigue/asthenia, grades 3-4 (21%)

            Neutropenia, grades 3-4 (20%)

            Weight loss, grades 1-4 (17%)

            Alopecia, grades 1-4 (14%)

            Diarrhea, grades 3-4 (13%)

            Vomiting, grades 3-4 (11%)

            1-10%

            Early diarrhea, grades 3-4 (9%)

            Nausea, grades 3-4 (8%)

            Dehydration (4-8%)

            Anemia, grades 3-4 (6%)

            Increased ALT, grades 3-4 (6%)

            Hyponatremia, grades 3-4 (5%)

            Cholinergic reactions, other than diarrhea (4.5%)

            Decreased appetite, grades 3-4 (4%)

            Stomatitis, grades 3-4 (4%)

            Hypophosphatemia, grades 3-4 (4%)

            Late diarrhea, grades 3-4 (3%)

            Sepsis (3-4%)

            Neutropenic fever/neutropenic sepsis (3%)

            Gastroenteritis (3%)

            IV catheter-related infection (3%)

            Infusion reactions (3%)

            Pyrexia, grades 3-4 (2%)

            Weight loss, grades 3-4 (2%)

            Thrombocytopenia, grades 3-4 (2%)

            Hypoalbuminemia, grades 3-4 (2%)

            Hypokalemia, grades 3-4 (2%)

            Hypocalcemia, grades 3-4 (1%)

            Alopecia, grades 3-4 (1%)

            Previous
            Next:

            Warnings

            Black Box Warnings

            Neutropenic sepsis

            • Fatal neutropenic sepsis occurred in 0.8% of patients receiving irinotecan liposomal
            • Severe or life-threatening neutropenic fever or sepsis occurred in 3% and severe or life-threatening neutropenia occurred in 20% of patients receiving irinotecan liposomal in combination with fluorouracil and leucovorin
            • Withhold drug for absolute neutrophil count <1500/mm³ or neutropenic fever
            • Monitor blood cell counts periodically during treatment

            Diarrhea

            • Severe diarrhea occurred in 13% of patients receiving irinotecan liposomal in combination with fluorouracil and leucovorin
            • Do not administer to patients with bowel obstruction
            • Withhold for diarrhea of grade 2-4 severity (see Dosage Modifications)
            • Administer loperamide for late-onset diarrhea of any severity
            • Administer atropine, if not contraindicated, for early-onset diarrhea of any severity

            Contraindications

            Hypersensitivity

            Cautions

            Can cause severe or life-threatening neutropenia and fatal neutropenic sepsis (see Black Box Warnings)

            Can cause severe and life-threatening diarrhea; do not administer to patients with bowel obstruction (see Black Box Warnings)

            Can cause severe and fatal interstitial lung disease; withhold drug in patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation

            Severe hypersensitivity reactions may occur, including anaphylaxis; permanently discontinue if a severe hypersensitivity reaction occurs

            Based on animal data with irinotecan HCl and the mechanism of action of irinotecan liposomal, can cause fetal harm when administered to a pregnant woman (see Pregnancy)

            Strong CYP3A4 inducers are known to substantially decrease systemic exposure to irinotecan or its active metabolite, SN-38

            Strong CYP3A4 or UGT1A1 inhibitors have shown to increase systemic exposure to irinotecan or its active metabolite, SN-38

            Previous
            Next:

            Pregnancy

            Pregnancy

            Based on animal data with irinotecan HCl and the mechanism of action of irinotecan liposomal, can cause fetal harm when administered to a pregnant woman

            Advise females of reproductive potential to use effective contraception during treatment and for 1 month after the final dose

            Embryotoxicity and teratogenicity were observed following treatment with irinotecan HCl, at doses resulting in irinotecan exposures lower than those achieved with irinotecan liposomal 70 mg/m² in humans, when administered to pregnant rats and rabbits during organogenesis

            Male reproductive recommendations

            • Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment and for 4 months after the final dose

            Lactation

            Unknown if distributed in human breast milk

            Because of the potential for serious adverse reactions in breastfed infants from irinotecan liposomal, advise a nursing woman not to breastfeed during treatment with and for 1 month after the final dose

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Binds to topoisomerase-1

            Topoisomerase-1 relieves torsional strain in DNA by inducing single-strand breaks

            Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase-1 DNA complex and prevent re-ligation of the single-strand breaks, leading to exposure time-dependent double-strand DNA damage and cell death

            Absorption

            Peak plasma concentration: 37.2 mcg/mL; 5.4 ng/mL (SN-38)

            AUC: 1364 h·mcg/mL; 620 h·mcg/mL (SN-3

            Distribution

            Vd: 4.1 L; 95% remains encapsulated

            Metabolism

            Metabolism of irinotecan liposome has not been evaluated

            Irinotecan is subject to extensive metabolic conversion by various enzyme systems, including esterases to form the active metabolite SN-38, and UGT1A1 mediating glucuronidation of SN-38 to form the inactive glucuronide metabolite SN-38G

            Irinotecan can also undergo CYP3A4-mediated oxidative metabolism to several inactive oxidation products, one of which can be hydrolyzed by carboxylesterase to release SN-38

            Elimination

            Half-life: 25.8 hr; 67.8 hr (SN-38)

            Clearance: 0.2 L/hr

            Excretion: 11-20% urine (SN-38 <1%); 25-50% cumulative biliary and urinary (parent drug and metabolites over 48 hr

            Pharmacogenomics

            Homozygous for UGT1A1*28 allele

            • Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia from irinotecan HCL
            • In clinical trials, patients homozygous for the UGT1A1*28 allele (N=7) were initiated on irinotecan liposomal (Onivyde) at a reduced dose of 50 mg/m² in combination with 5-fluorouracil/leucovorin
            • The frequency of grade 3 or 4 neutropenia in these patients (2 of 7 [28.6%]) was similar to the frequency in patients not homozygous for the UGT1A1*28 allele who received a starting dose of irinotecan liposomal of 70 mg/m² (30 of 110 [27.3%])
            Previous
            Next:

            Administration

            IV Compatibilities

            Dextrose 5% water

            0.9% NaCl

            IV Preparation

            Withdraw the calculated volume for dose from the vial

            Dilute in 500 mL D5W or 0.9% NaCl and mix diluted solution by gentle inversion

            Protect diluted solution from light

            Administer diluted solution within 4 hr of preparation when stored at room temperature or within 24 hr of preparation when stored under refrigerated conditions

            IV Administration

            Allow diluted solution to come to room temperature prior to administration if stored under refrigeration

            Premedicate with a corticosteroid and an antiemetic 30 minutes before administering irinotecan liposomal

            Infuse diluted solution IV over 90 minutes

            Do not use in-line filters

            Discard unused portion

            Storage

            Cytotoxic drug; follow applicable special handling and disposal procedures

            Unopened vials

            • Store vials refrigerated at 2-8ºC (36-46°F)
            • Do not freeze
            • Protect from light

            Diluted solution

            • Administer diluted solution within 4 hr of preparation when stored at room temperature or within 24 hr of preparation when stored under refrigerated conditions (2-8ºC [36-46ºF])
            • Protect diluted solution from light
            • Allow diluted solution to come to room temperature prior to administration
            • Do not freeze
            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.